The United States of America, As Represented by the Secretary, Department of Health and Human Services

Children's Hospital Medical Center

Katelyn Melgar

Craig J Thomas

Jian-kang Jiang

Daniel T Starczynowski

Garrett W Rhyasen

Morgan MacKenzie Walker

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same. 

Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein. 

Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors

Growing community of inventors

Cincinnati, OH, United States of America

Katelyn Melgar